Automatic tube type magnetic particle indirect chemiluminescence |
240T/h for single instrument,up to 960T/h for Four instruments online |
Intra-batch repeatability, CV≤5% |
Carry-over rate, ≤0.1ppm |
30 reagent positions, supporting multi-package combination |
240 sample positions, high-throughput injection system |
Refrigerated reagent position, loading of reagent and consumables without shutdown |
Three separate sample track design, surpport STAT use |
High stability and low maintainability |
Accurate sample loading: Liquid level follow system, with the sample loading parameter of 10-200uL, meeting different sample requirements
Accurate temperature control: 37±0.2°C
Intra-batch repeatability: CV≤5%
Low carry-over rate : The needle tip is of conical structure, ≤0.1ppm (carry-over rate )
Fourth step cleaning: unique magnetic separation cleaning, ultra-low magnetic bead loss rate
High cup cleaning efficiency: Built-in sensor
Constant throughput: No deceleration for sample testing, throughput 240T/h, and up to 960T/h in 4 online instruments
Stability: Low fault rate and low maintenance cost
High sensitivity reaction system: ALP chemiluminescence reaction system, with advantages in small molecule test
High sensitivity substrate: Enhanced AMPPD chemiluminescence substrate with sensitivity up to 10-18 moL
User-friendly software: Easy to operate with a simple interface
Unique row cup system: Unattended for up to 6 hours when fully loaded
Priority for emergency treatment: Separate emergency channel
Intuitive and convenient consumable management: One-stop design, intelligent reminder
Automatic chemiluminescence immunoassay analyzer: CN202110661101.3
A gripper robot arm for automatic chemiluminescence immunoassay analyzer: CN202120717767.1
Automatic loading and dispatching mechanism of RV cuvette: CN202120721367.8
Calibration mechanism of a photomultiplier: CN202121642170.1
Enclosure of automatic chemiluminescence immunoassay analyzer: CN202130195641.8
Sample rack: CN202130448989.3
Gastric | Thyroid | Tumor | Endocrine | Inflammation | Diabetes | Liver Fibrosis | |
PGI | TSH | AFP | CEA | FSH | PCT | C-P | PIIINP |
PGII | FT3 | CA125 | CA15-3 | PRL | IL-6 | INS | LN |
G-17 | FT4 | tPSA | fPSA | LH | SAA | HA | |
TT4 | CA72-4 | CA19-9 | P | CRP* | CIV | ||
TT3 | CYFRA21-1 | SCC | T | CG | |||
TG | NSE | HE4 | E2 | ||||
Anti-TPO | Ferr | CA50 | β-HCG | ||||
Anti-TG | CA242 | proGRP* | AMH | ||||
TRAb* | β2-MG* | PIVKA-II** | SHBG* | ||||
fE3* | |||||||
F-hCGβ* |
Infectious Diseases | Cardiac | Hypertension | Growth Hormone | Anemia | Bone metabolism |
Pre S1** | CK-MB* | ALD** | IGF-I* | VB12* | iPTH* |
HBeAg** | D-Dimer* | Cor** | hGH* | FA* | 25-OH-Vit-D* |
HBsAg** | cTnT* | ACTH** | BGP* | ||
HBeAb** | hs-cTnI* | DR** | CT* | ||
HBsAb** | MYO* | Ang II** | |||
HBcAb** | LP-PLA2* | ||||
Anti-HCV** | BNP* | ||||
HIV** | NT-proBNP* | ||||
IGRA** | GAD65* | ||||
Anti-TP** | H-FABP* | ||||
HCY* |
Launched in December 2022 (*) under development (**)